In short
Clinical trials investigating VANDETANIB are studying its role in people with RET-mutant medullary thyroid cancer. These trials look at how well it works compared with other treatments and measure outcomes such as progression-free survival. The main focus is on patients with progressive, advanced disease who have not had prior kinase inhibitor treatment.
Key points
- Clinical trials investigating VANDETANIB are focused on RET-mutant medullary thyroid cancer. The main study is a Phase 3 trial in patients with progressive, advanced disease who have not had prior kinase inhibitor treatment. It compares VANDETANIB-related treatment against other options to see which works better. The main outcome being measured is progression-free survival, checked by independent review. The trial is authorised and plans to enroll 273 patients.
Clinical trial overview
The available trial is a Phase 3 study in RET-mutant medullary thyroid cancer. It compares selpercatinib with cabozantinib or VANDETANIB in patients with progressive, advanced disease.
The study is interventional, which means people in the trial receive a treatment so researchers can compare results between groups. The trial is authorised and includes 273 participants.
Who can join the study
This trial is for patients with progressive, advanced, kinase inhibitor naïve, RET-mutant medullary thyroid cancer. “Kinase inhibitor naïve” means the patient has not had this type of cancer medicine before.
The study population is therefore a specific group of thyroid cancer patients with a RET gene change and disease that is already advanced or getting worse.
What the trial is measuring
The main outcome is progression-free survival (PFS) by BICR. PFS means the time patients live without their cancer getting worse.
BICR means blinded independent central review, so independent experts review the results without knowing which treatment each patient received. This helps make the comparison between treatments more objective.
Study design and phase
The study title shows that VANDETANIB is part of a comparison against selpercatinib and cabozantinib. This type of design helps researchers see which treatment may work better in this cancer group.
Because it is a Phase 3 trial, it is a later-stage study meant to test treatment benefit in a larger group of patients.
Trial status and size
The trial status is Authorised. The planned enrollment is 273 patients.
Only one trial record was provided, so this article focuses on that study and its main goal: comparing treatment outcomes in RET-mutant medullary thyroid cancer.